AstraZeneca and Lilly join forces to develop AD drug
Pharmaceutical companies, AstraZeneca and Eli Lilly and Co (Lilly) announced on 16 September having reached an agreement to jointly develop and commercialise AZD3293, an oral BACE inhibitor currently...
View ArticleEli Lilly, AstraZeneca Launch Pivotal Clinical Trial For Early Alzheimer’s...
Eli Lilly and Company and AstraZeneca announced the start of recruitment of patients for the Phase II/III AMARANTH clinical trial of an inhibitor of beta secretes cleaving enzyme (BACE), currently...
View ArticleGenentech Brain Trust Leaves With $217 Million For New Startup To Fight...
Three former top researchers at Genentech (now part of Roche Holding), have raised $217 million in venture capital to start a new company, Denali Therapeutics, focused on treating and curing...
View ArticleAlzheimer’s and Parkinson’s diseases featured in latest IMI 2 call
The Innovative Medicines Initiative (IMI) has launched a new call for research proposals that will aim to accelerate the development of medicines in a number of key areas, including neurological...
View ArticleEMA opens consultation on revised guidelines on medicines to treat...
The European Medicines Agency (EMA) has released draft revised guidelines on medicines for the treatment of Alzheimer’s disease and other types of dementias for a six-month public consultation. EMA...
View ArticleStudy identifies memory suppressor gene
While research has identified hundreds of genes required for normal memory formation, genes that suppress memory are of special interest because they offer insights into how the brain prioritizes and...
View ArticleAntibody Reduces Harmful Amyloid Plaques in Alzheimer’s Patients, New Study...
Aducanumab, an antibody developed by the University of Zurich, has been shown to trigger a meaningful reduction of harmful beta-amyloid plaques in patients with early-stage Alzheimer’s disease. These...
View Article